Skip to main content
S&P 5007,656.98+0.86%DOW52,573.29+0.98%NASDAQ26,333.03+0.96%BTC$77,267.00+0.58%ETH$2,510.86+2.27%GOLD$4,390.00-0.39%OIL$99.99-2.43%
Smart Investors Daily
QN

NASDAQ · QNTM

Quantum BioPharma Ltd.

Healthcare · Drug Manufacturers - Specialty & Generic

$3.20

Down-$0.09 (-2.74%)

Updated Sep 14, 2026, 1:39 AM

SID Score

4.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
37.41M
P/E ratio
-1.1
Dividend yield
0.00%
52-week range
$2.07 – $21.00
Volume
200.79K
Avg. volume
120.46K

Price performance

QNTM price history

1M range · 19 trading sessions · Daily adjusted prices

QNTM closed at $3.20 after 19 trading sessions, down 13.04% for the selected period.

Last close
$3.20
Period change
-13.04%
Period low
$2.95
Period high
$3.68
Daily close
View OHLC price history
QNTM OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 11, 2026$3.32$3.3899$3.20$3.20200.79K
Sep 10, 2026$3.54$3.60$3.0815$3.29239.08K
Sep 9, 2026$3.34$3.7387$3.33$3.58445.64K
Sep 8, 2026$3.28$3.37$3.06$3.29131.19K
Sep 4, 2026$3.01$3.27$2.99$3.24110.98K
Sep 3, 2026$3.10$3.19$2.9101$2.95114.17K
Sep 2, 2026$3.07$3.14$3.00$3.0851.43K
Sep 1, 2026$3.14$3.2331$3.02$3.0483.22K
Aug 31, 2026$3.02$3.23$3.02$3.1782.25K
Aug 28, 2026$3.15$3.21$3.07$3.07587.32K
Aug 27, 2026$3.08$3.24$3.03$3.1358.82K
Aug 26, 2026$3.28$3.37$3.06$3.07124.18K
Aug 25, 2026$3.36$3.43$3.1204$3.28143.78K
Aug 24, 2026$3.44$3.45$3.1264$3.24205.52K
Aug 21, 2026$3.49$3.58$3.35$3.44137.94K
Aug 20, 2026$3.52$3.52$3.3595$3.44149.82K
Aug 19, 2026$3.61$3.85$3.27$3.52280.6K
Aug 18, 2026$3.68$3.7305$3.23$3.34310.84K
Aug 17, 2026$3.98$4.20$3.465$3.681.22M

Latest QNTM news

The latest Smart Investors Daily articles mentioning QNTM.

Stock researchCompany · Overview

QNTM research

Overview

Company profile and research snapshot.

Company profile

Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$33.28
Implied upside
—
Analysts
7
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 9, 2026

Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment

NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, “A Micro-Cap Biotech Just Cleared a Milesto

Yahoo · Sep 1, 2026

Quantum BioPharma Announces Plans to Voluntarily Delist its Class B Shares from the Canadian Securities Exchange

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and meta

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By